Opzelura (Ruxolitinib)

Ruxolitinib, the active ingredient in Opzelura, is a JAK inhibitor presented as a cream for topical use. It treats atopic dermatitis and vitiligo in adults and adolescents, reducing inflammation and abnormal pigment loss.

GNH USA supplies Opzelura as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Opzelura, a topical JAK inhibitor, is used for inflammatory skin conditions.

Atopic dermatitis: reduces erythema, itching, and skin barrier disruption. Vitiligo: promotes repigmentation of depigmented patches. Inflammatory skin disorders: modulates immune response to lessen lesion formation.

Adverse reactions may occur with topical ruxolitinib use.

Common Side Effects: - Application site irritation: redness or discomfort at the site. - Burning sensation: transient heat feeling after application. - Itching: mild pruritus localized to treated area. - Dry skin: increased scaling or flaking. - Headache: occasional mild headache unrelated to skin. - Acneiform eruption: small pimples may appear.

Serious or Rare Side Effects: - Skin infection: secondary bacterial or fungal infection of treated area. - Allergic reaction: urticaria, angioedema, or systemic rash. - Skin discoloration: unexpected hyper‑ or hypopigmentation. - Severe dermatitis: extensive eczema or contact dermatitis. - Malignancy suspicion: rare reports of skin cancer development.

When using Opzelura, consider the following safety measures.

Avoid use on infected or broken skin: wait until lesions are healed. Limit application area: do not exceed prescribed surface area. Monitor for signs of infection: seek medical advice if redness spreads. Use with caution in immunocompromised patients: increased infection risk. Do not combine with other topical steroids without guidance: may enhance irritation. Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Topical ruxolitinib may interact with other agents that affect skin immunity.

Major Interactions (Avoid): - Systemic JAK inhibitors: concurrent use may increase immunosuppression. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise systemic exposure. - Phototherapy: combined use can heighten skin sensitivity.

Moderate Interactions (Monitor Closely): - Other topical immunosuppressants (e.g., tacrolimus): monitor for additive irritation. - Antifungal creams: assess for overlapping skin reactions. - Live vaccines: evaluate timing to avoid reduced vaccine efficacy.